The board of Par Pharmaceutical has approved the promotions of Thomas Haughey to the role of president and Paul Campanelli to chief operating officer, effective immediately. Both men will continue to report to Patrick LePore, who retains his title of chairman and chief executive.
LePore said: ‘With the acquisition of Anchen and the pending acquisition of Edict, Par is becoming a larger and more complex organisation with three diverse locations and more than 300 additional employees.
‘These new challenges and opportunities require a president and chief operating officer to effectively to manage the company and its subsidiaries.’
Haughey has been chief administrative officer of Par since 2008, executive vice president since 2006 and general counsel and secretary since joining the firm in 2003. He brings more than 25 years of accounting, legal and pharmaceutical experience to his new role.
In addition to his title as chief operating officer, Campanelli will retain the title of president, Par Pharmaceutical (generics division) and assume responsibility for Strativa Pharmaceuticals (branded division). He began his career at Par in 2001 as senior director, business development and has held positions of increasing responsibility.
Par Pharmaceutical makes two promotions
To manage the expanded company and its subsidiaries
